ZINC ACETATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C2H3O2.Zn.2H2O
Molecular Weight	219.528
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.[Zn++].CC([O-])=O.CC([O-])=O

InChI

InChIKey=BEAZKUGSCHFXIQ-UHFFFAOYSA-L

InChI=1S/2C2H4O2.2H2O.Zn/c2*1-2(3)4;;;/h2*1H3,(H,3,4);2*1H2;/q;;;;+2/p-2

HIDE SMILES / InChI

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 41 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 8297
respiratory burst 39 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1430
transformed cell apoptotic process 108 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1430
Methotrexate 38 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 38
ultraviolet B-induced damage 38 Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 323
T cell mediated immunity 40 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1430
Zinc transporter ZIP1 38 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1064
Zinc transporter ZIP2 38 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1064

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Unknown 2578
Caries 43 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 123 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 8429	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date 1955
Zinc deficiency 39 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 136 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 8429	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 2012
Diaper dermatitis 38 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 8429	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 2006
Poison Ivy dermatitis 38 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 8429	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 95 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 8429	ZINC SULFATE Approved Use Unknown Launch Date 1987
Mucositis 39 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 656	ZINC SULFATE Approved Use Unknown Launch Date 1987
Dysgeusia 38 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 656	ZINC SULFATE Approved Use Unknown Launch Date 1987
Unknown 2578

PubMed

Title	Date	PubMed
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.	1993 Aug	8404763
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.	1997 Feb	9021177
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.	1997 May 16	11671728
Thujaplicin-copper chelates inhibit replication of human influenza viruses.	1998 Aug	9806486
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.	1999 May	10327022
Inhibition of HIV-1 infection by zinc group metal compounds.	1999 Sep	10517314
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.	2000 Sep	10978858
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.	2002 Mar 1	11877378
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.	2004	16145958
Thermotoga maritima-Escherichia coli chimeric topoisomerases. Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis.	2004 Jul 16	15140883
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.	2004 Jul 16	15131129
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.	2004 Jul 30	15161915
High-throughput computational and experimental techniques in structural genomics.	2004 Oct	15489337
Impact of the mother's zinc deficiency on the woman's and newborn's health status.	2005	16240669
Erythrocyte zinc content in critically ill patients.	2005	16176172
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections].	2005	15901979
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.	2005 Apr 27	15857667
Zinc in attention-deficit/hyperactivity disorder.	2005 Aug	16190793
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.	2005 Aug	16042674
[Reduced thymulin production during occupational exposure to lead].	2005 Jan-Mar	15915658
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.	2005 May	15883427
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.	2005 Nov-Dec	16277018
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.	2005 Sep 1	16118778
Effects of zinc supplementation in patients with type 1 diabetes.	2005 Summer	16034148
Characterization and inhibition of SARS-coronavirus main protease.	2006	16611148
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.	2006 Apr	16608609
Copper and zinc concentrations in serum of healthy Greek adults.	2006 Apr 15	15955548
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.	2006 Dec	17093223
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.	2006 May	16636303
Zinc homeostasis in aging: two elusive faces of the same "metal".	2006 Summer	16706668
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.	2010 Dec	20729176
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.	2010 Dec 1	20851137
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?	2011 Mar 1	21220601
Glucarpidase for the treatment of life-threatening methotrexate overdose.	2012 Nov	23170306
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.	2013 Dec	24060544
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.	2013 Jan	22083529
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.	2013 Jul 31	23726862
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.	2013 Mar	23232460
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.	2013 Nov 25	24120544
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.	2013 Sep	23352990
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.	2014 Jan	23832296
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.	2014 May	24132809
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.	2014 May 15	24780487
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.	2014 May 16	24631018
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.	2014 Nov 4	25127755
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.	2015 Sep	25940351
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.	2015 Sep	25631103
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.	2016 Oct 1	27546855
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.	2016 Sep	26892107
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.	2017 May 15	28214427

Patents

Sample Use Guides

In Vivo Use Guide

Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.

Route of Administration: Oral

In Vitro Use Guide

Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.

Name

Type

Language

ZINC ACETATE

Systematic Name

English

ZINC ACETATE [MART.]

Common Name

English

ZINC ACETATE [USP MONOGRAPH]

Common Name

English

WILZIN

Brand Name

English

ZINC ACETATE DIHYDRATE [MI]

Common Name

English

ZINC ACETATE [HSDB]

Common Name

English

ZINC ACETATE [II]

Common Name

English

Zinc acetate dihydrate [WHO-DD]

Common Name

English

ZINC ACETATE [WHO-IP]

Common Name

English

ZINC ACETATE [ORANGE BOOK]

Common Name

English

ACETIC ACID, ZINC SALT, HYDRATE (2:1:2) [WHO-IP]

Common Name

English

ZINCI ACETAS [WHO-IP LATIN]

Common Name

English

ZINC ACETATE DIHYDRATE [MART.]

Common Name

English

ZINC ACETATE HYDRATE [JAN]

Common Name

English

PC-1005 COMPONENT ZINC ACETATE DIHYDRATE

Common Name

English

ZINC ACETATE COMPONENT OF DEPINAR

Common Name

English

NPC-02

Code

English

ZINC ACETATE HYDRATE

Systematic Name

English

ZINC ACETATE DIHYDRATE COMPONENT OF PC-1005

Common Name

English

ZINC ACETATE [VANDF]

Common Name

English

ACETIC ACID, ZINC SALT, DIHYDRATE

Common Name

English

ZINC ACETATE [USP-RS]

Common Name

English

ZINC ACETATE DIHYDRATE [EP MONOGRAPH]

Common Name

English

DEPINAR COMPONENT ZINC ACETATE

Common Name

English

Zinc acetate dihydrate

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

11185